25706-30-3

Basic information

• Product Name: (4-aminophenyl)(2-thienyl)methanone
• Synonyms: (4-aminophenyl)(2-thienyl)methanone;methanone, (4-aminophenyl)-2-thienyl-;(4-aminophenyl)(2-thienyl)methanone hydrochloride
• CAS NO: 25706-30-3
• Molecular Formula: C₁₁H₉NOS
• Molecular Weight: 203.26
• Mol File: 25706-30-3.mol

Chemical Properties

• Melting Point: 120.5-122.1 °C(Solv: ethanol (64-17-5))
• Boiling Point: 390.0±22.0 °C(Predicted)
• Appearance: /
• Density: 1.275±0.06 g/cm3(Predicted)
• PKA: 1.50±0.10(Predicted)
• CAS DataBase Reference: (4-aminophenyl)(2-thienyl)methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (4-aminophenyl)(2-thienyl)methanone(25706-30-3)
• EPA Substance Registry System: (4-aminophenyl)(2-thienyl)methanone(25706-30-3)

Safety Data

• Hazardous Substances Data: 25706-30-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(4-aminophenyl)(2-thienyl)methanone is used as a potential therapeutic agent for conditions such as cancer, diabetes, and inflammation. Its pharmacological properties make it a promising candidate for drug design and medicinal chemistry.
Used in Material Science:
(4-aminophenyl)(2-thienyl)methanone is used in the development of new materials and as a building block for organic synthesis. Its unique chemical structure allows for the creation of novel compounds with potential applications in various industries.

Upstream product

• 4153-45-1 2-(4-chlorobenzoyl)thiophene 
• 4160-65-0 (4-bromophenyl)(thien-2-yl)methanone 
• 122-01-0 4-chloro-benzoyl chloride 
• 34715-92-9 (4-nitro-phenyl)-thiophen-2-yl-methanone 

Downstream Products

• 109455-16-5 [4-(N'-methyl-thioureido)-phenyl]-[2]thienyl ketone 
• 141691-44-3 (4-Pyrrol-1-yl-phenyl)-thiophen-2-yl-methanone 
• 141691-46-5 (4-Pyrrol-1-yl-phenyl)-thiophen-2-yl-methanol 
• 141691-53-4 1-[(4-Pyrrol-1-yl-phenyl)-thiophen-2-yl-methyl]-1H-imidazole 

Relevant articles and documents

Urea thiadiazole inhibitors of plasminogen activator inhibior-1

Methods of treating disorders associated with elevated levels of PAI-1 are disclosed comprising administering to a patient in need thereof a therapeutically effective amount of at least one compound of formula (I), or a pharmaceutically-acceptable salt, prodrug, stereoisomer or solvate thereof, wherein: A is aryl o heteroaryl, and R1-R12, are defined herein. The invention also pertains to pharmaceutical compositions and compounds within the scope of formula (I) as well as medicaments and articles of manufacture comprising compounds of formula (I).